AstraZeneca's blockbuster breast cancer drug Enhertu will be added to China's state-run health insurance scheme from Jan. 1, ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

AstraZeneca's Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that ...

China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance, a move ...

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...

The findings show that the AstraZeneca drug can also be used during the emergency of a life-threatening attack to reduce the ...

A new study, supported by AstraZeneca, has shown that a single dose of benralizumab significantly reduces treatment failure ...

AstraZeneca (AZN) reported positive results from a Phase 3 study of its drug Truqap in the treatment of a certain type of ...

AstraZeneca Pharmaceuticals LP violated federal and Ohio law when it denied a Christian sales specialist an exemption from ...

The IL-5 inhibitor is already available under the Fasenra brand name for maintenance use in severe eosinophilic asthma, but a ...

The failure of the trial of the drug AZD4041 by pharma giant AstraZeneca, to combat opioid use disorder (OUD), highlights the ...